Xinhua Media+丨The latest edition of the National Medical Insurance Drug List announces 74 new drugs for medical insurance
Xinhua News Agency, Beijing, December 3 (Reporters Peng Yunjia and Zhao Jiulong) The adjustment results of the latest edition of the National Medical Insurance Drug List are "released."
The National Medical Security Administration held a press conference in Beijing on the 3rd to introduce that after this adjustment, 74 new drugs entered the catalog, including 67 exclusive drugs imported through negotiation and 7 non-exclusive drugs imported directly, including the exclusive drugs successfully negotiated. The average price cut was 61.71%.
The reporter learned that 117 drugs were included in the scope of the negotiation of the medical insurance drug list. From the results of the negotiations, 94 drugs were successfully negotiated, with a success rate of 80.34%.
In addition, 11 drugs with low clinical value, strong substitutability, and small purchases on the national recruitment platform in recent years have been transferred out of the original catalog.
It is reported that the newly included drugs in this adjustment involve a total of 21 clinical groups, supplementing the needs of drugs for tumors, chronic diseases, anti-infectives, rare diseases, women and children, and patients benefit widely.
For example, otuzumab injection used for the treatment of lymphoma, Alzheimer's medicine mannote sodium capsule, diabetes medicine smeglutide injection and so on.
This adjustment has achieved another price reduction of some drugs in the catalog, freeing up fund space for more cost-effective drugs, and successfully realizing the upgrade of drug security.
At the same time, under the premise of ensuring the safety of the fund, the payment restrictions for some drugs have been cancelled, expanding the beneficiary population, and greatly improving the availability of drugs and the fairness of drug use.
It is worth noting that this adjustment includes 7 drugs for the treatment of rare diseases to further alleviate the economic burden of patients.
Including Noxinassen sodium injection for the treatment of spinal muscular atrophy, fampridine sustained-release tablets for the treatment of multiple sclerosis, and concentrated solution for injection of agalsidase α for the treatment of Fabry disease.
Huang Huabo, Director of the Medical Service Management Department of the National Medical Insurance Administration, said that since the establishment of the National Medical Insurance Administration, the National Medical Insurance Drug Catalogue has been adjusted for 4 consecutive years. A total of 507 drugs have been added to the scope of national medical insurance payment. At the same time, a batch of " "Zombie drugs" etc. bring up the catalog.
After the adjustment of the catalogue, the total number of drugs in the national medical insurance drug catalogue is 2,860, of which 1,486 are Western medicines and 1,374 are Chinese patent medicines.
The number of Chinese herbal medicines in the catalog has not been adjusted, and there are still 892 types.